Axonal Neuregulin 1 Type III Activates NF-κB in Schwann Cells during Myelin Formation

Limpert, Allison S.; Carter, Bruce D.

doi:10.1074/jbc.m109.098780

Cited by 33 publications

(31 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies have demonstrated that NF-B is essential for myelin formation (especially in the PNS), although sometimes with conflicting results Jessen and Mirsky, 2008;Limpert and Carter, 2010;Limpert et al, 2013;Morton et al, 2013;Nickols et al, 2003;Yoon et al, 2008). Myelin basic protein has been identified as one direct gene target of NF-B (Nickols et al, 2003).…”

Section: Nuclear Factor (Nf)-äb Regulationmentioning

confidence: 98%

Relationships between cobalamin, epidermal growth factor, and normal prions in the myelin maintenance of central nervous system

Scalabrino

Veber

Tredici

2014

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Section: Nuclear Factor (Nf)-äb Regulationmentioning

confidence: 98%

Relationships between cobalamin, epidermal growth factor, and normal prions in the myelin maintenance of central nervous system

Scalabrino

Veber

Tredici

2014

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Section: Nrg1 Signaling In Scsmentioning

confidence: 99%

“…A further example of interaction between these pathways is that type III NRG1 and cAMP-dependent PKA phosphorylation act cooperatively to increase the activity of NF-κB, which promotes myelination [69,70].…”

Section: Nrg1 Signaling In Scsmentioning

confidence: 99%

“…Crucially, cAMP appears to switch NRG1 from a proliferative signal to a myelin differentiation signal [62]. A further example of interaction between these pathways is that type III NRG1 and cAMP-dependent PKA phosphorylation act cooperatively to increase the activity of NF-κB, which promotes myelination [69,70].A nuclear-localized form of erbB3 (nuc-erbB3) has recently been described, the expression of which is regulated by the addition of exogenous NRG1. Nuc-erbB3 is expressed in postnatal SCs in rats, but is not detected in adulthood, suggesting developmental regulation.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Role of Neuregulin-1 In the Response To Nerve Injury

Fricker

Bennett

2011

Future Neurol.

View full text Add to dashboard Cite

Axons and Schwann cells exist in a highly interdependent relationship: damage to one cell type invariably leads to pathophysiological changes in the other. Greater understanding of communication between these cell types will not only give insight into peripheral nerve development, but also the reaction to and recovery from peripheral nerve injury. The type III isoform of neuregulin-1 (NRG1) has emerged as a key signaling factor that is expressed on axons and, through binding to erbB2/3 receptors on Schwann cells, regulates multiple phases of their development. In adulthood, NRG1 is dispensable for the maintenance of the myelin sheath; however, this factor is required for both axon regeneration and remyelination following nerve injury. The outcome of NRG1 signaling depends on interactions with other pathways within Schwann cells such as Notch, integrin and cAMP signaling. In certain circumstances, this signaling pathway may be maladaptive; for instance, direct binding of Mycobacterium leprae onto erbB2 receptors produces excessive activation and can actually promote demyelination. Attempts to modulate this pathway in order to promote nerve repair will therefore need to give consideration to the exact isoform used, as well as how it is processed and the context in which it is presented to the Schwann cell. Keywordsneuregulin-1; neuropathy; peripheral nerve injury; regeneration; remyelination; repair; Schwann cell Peripheral nerve injury causes significant morbidity and reduced quality of life as a consequence of weakness, sensory loss and neuropathic pain. In total, 6% of the elderly population suffer from peripheral neuropathy [1], which can be caused by metabolic diseases such as diabetes, inherited genetic disorders such as Charcot-Marie-Tooth disease, infectious and inflammatory disorders including Guillan-Barré syndrome and traumatic injury to the nerve (which alone effects up to 300,000 people in Europe per year [1,2]). In contrast to the CNS, peripheral nerves have a significant regenerative capacity [3]; however, in patients, regeneration and the clinical outcome are often poor. Axons regenerate at a rate of approximately 1 mm per day, depending on the site of the lesion. There may be a delay of months if not years before the target zone is re-innervated, and by this time, the target organ and supporting cells may have irreversibly changed, becoming much less receptive to reinnervation. The current approaches to peripheral nerve repair following nerve transection are either to surgically suture the nerve or to bridge the gap between the two cut ends. Financial & competing interests disclosureThe authors have no other rel evant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Europe PMC Funders Group NRGs & the PNSNRGs Neuregulins are a family of growth factors en...

show abstract

“…Acting through ErbB receptors, NRG1 stimulates SC mitogenesis and myelination through signaling via the ERK and PI3-K pathways, an effect enhanced by cAMP [103,104]. Myelinating effects of NRG1 are also exerted through NF-κB activation [105,106], again enhanced by cAMP [107] as well as MAPK to drive cell proliferation and PI3K/Akt to prevent apoptosis. As mentioned above, Kao described an additional pathway downstream from ErbB, in which NRG1 acts through the protein phosphatase calcineurin to directly Fig.…”

Section: Molecular Mechanisms Underlying the Differentiation Of Neuramentioning

confidence: 97%

Pluripotent Stem Cells for Schwann Cell Engineering

Boddeke

Copray

2014

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Tissue engineering of Schwann cells (SCs) can serve a number of purposes, such as in vitro SC-related disease modeling, treatment of peripheral nerve diseases or peripheral nerve injury, and, potentially, treatment of CNS diseases. SCs can be generated from autologous stem cells in vitro by recapitulating the various stages of in vivo neural crest formation and SC differentiation. In this review, we survey the cellular and molecular mechanisms underlying these in vivo processes. We then focus on the current in vitro strategies for generating SCs from two sources of pluripotent stem cells, namely embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Different methods for SC engineering from ESCs and iPSCs are reviewed and suggestions are proposed for optimizing the existing protocols. Potential safety issues regarding the clinical application of iPSC-derived SCs are discussed as well. Lastly, we will address future aspects of SC engineering.

show abstract

Axonal Neuregulin 1 Type III Activates NF-κB in Schwann Cells during Myelin Formation

Cited by 33 publications

References 50 publications

Relationships between cobalamin, epidermal growth factor, and normal prions in the myelin maintenance of central nervous system

Relationships between cobalamin, epidermal growth factor, and normal prions in the myelin maintenance of central nervous system

The Role of Neuregulin-1 In the Response To Nerve Injury

Pluripotent Stem Cells for Schwann Cell Engineering

Contact Info

Product

Resources

About